French drugmaker Sanofi-Aventis SA said Thursday a clinical trial showed its drug candidate iniparib did not improve survival or slow disease progression in patients with breast cancer.
Kansas City Star: Business, Kansas City Star: Business
Fri, 01/28/2011 - 4:49am
French drugmaker Sanofi-Aventis SA said Thursday a clinical trial showed its drug candidate iniparib did not improve survival or slow disease progression in patients with breast cancer.